Insights On CONTRACT PHARMA MANUFACTURING

  1. Why Innovator Companies Need To Take Control Of Their Supply Chains 5/12/2026

    Strategic control of materials and suppliers helps innovators cut risk, manage costs, and avoid disruptions as they scale — turning uncertainty into predictability and resilience.

  2. Accelerating ADC Analytical Method Development Through Platform Innovation 5/11/2026

    Leverage a platform-based analytical development strategy to accelerate ADC IND readiness through early CQA identification, reduced development risk, and streamlined progression from development to patients.

  3. Design Scalable Downstream Processes With Practical Strategies 5/11/2026

    Downstream purification is becoming more complex as new modalities enter development. Learn how advanced analytics and chromatography strategies can support scalable, confident process development.

  4. Unlock The Potential Of GPEx® Lightning: Accelerate Your HEK Cell Line Development 5/8/2026

    Cut HEK cell line development to four months with 30% higher titers. GPEx® Lightning delivers faster, scalable biologics manufacturing. Access the full summary now.

  5. Why Life Cycle Integration Is Critical To ADC And XDC Success 5/8/2026

    The ADC industry is expanding to supply targeted treatments to support unmet need and patient demand. To succeed, ADC developers must account for the manufacturing complexity of these molecules.

  6. From Insights To Impact: Predictive Models And PAT For More Efficient And Robust Biologics Manufacturing 5/8/2026

    Explore how advanced scale-up methodologies and real-time analytical technologies strengthen both drug substance and drug product manufacturing by enabling process understanding and informed decision-making.

  7. Spray Dried Biologics For Pulmonary Dosage Forms 5/8/2026

    View how spray drying enables stable, precisely engineered pulmonary powders for biologics, supporting efficient lung delivery, scalability, and preservation of molecular structure and activity.

  8. From 51% Yield To 87% With Targeted Impurity Removal 5/7/2026

    Targeted impurity identification and purification redesign dramatically improved yield, reduced process complexity, and enabled reliable API supply for Phase II clinical development.

  9. Overcoming Product Instability And Improving Yield 5/7/2026

    Early identification of hidden product instability enabled rapid process adjustments, improving yield and keeping a preclinical toxicology program on track despite challenging reaction conditions.

  10. Producing Quality APIs At Scale 5/7/2026

    Targeted process optimization transformed an early‑phase API with yield and impurity challenges into a scalable, high‑quality manufacturing process ready to support ongoing drug development.